LONDON--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced an update to their voluntary licensing ...
LONDON, July 14, 2025--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced data from the phase IIIb ...
GSK plc announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, has announced that the European Commission has authorised ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Following discontinuation of Vocabria and rilpivirine injection, it is essential to adopt an alternative, fully suppressive antiretroviral regimen no later than one month after the final injection of ...
LONDON--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that Health Canada has ...
(RTTNews) - GlaxoSmithKline plc (GSK, GSK.L) said Monday that its majority-owned specialist HIV company ViiV Healthcare has received the Marketing Authorisation for Vocabria (cabotegravir injection ...
ViiV Healthcare, a pharmaceutical company specialising in HIV, launched a campaign targeting Healthcare Providers (HCPs) to increase uptake of its new injectable HIV treatment, Cabenuva (Vocabria + ...
Multiple real-world studies show consistent high effectiveness of Vocabria Rekambys (cabotegravir rilpivirine LA (CAB+RPV LA)) across a broad range of populations Implementation science data for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results